Hepatocyte growth factor intervention to reduce myocardial injury and improve cardiac function on diabetic myocardial infarction rats.
Animals
Apoptosis
/ drug effects
Cardiotonic Agents
/ metabolism
Cell Survival
/ drug effects
Diabetes Mellitus, Experimental
/ complications
Hepatocyte Growth Factor
/ metabolism
Myocardial Infarction
/ complications
Myocardium
/ pathology
Proto-Oncogene Proteins c-met
/ metabolism
Rats, Sprague-Dawley
Journal
European journal of histochemistry : EJH
ISSN: 2038-8306
Titre abrégé: Eur J Histochem
Pays: Italy
ID NLM: 9207930
Informations de publication
Date de publication:
30 Jul 2020
30 Jul 2020
Historique:
received:
25
05
2020
accepted:
29
06
2020
entrez:
10
9
2020
pubmed:
11
9
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Acute myocardial infarction (AMI) is recognized to be a severe threat to people's health conditions and life quality. The accumulation of hepatocyte growth factor (HGF) in ischemic myocardium has been observed in both processes of experimental ischemia and reperfusion (I/R) and permanent coronary artery occlusion. The aim of the study was to investigate the effect of HGF on myocardial cell apoptosis, ventricular remodeling and cardiac function after myocardial infarction (MI) in diabetic rats, and to explore whether the effect is mediated by HGF/c-Met signaling pathway. MI significantly increases LVWI and RVWI and myocardial apoptotic index, and up-regulates the expression of HGF and c-Met at mRNA and protein levels in MI control group. The LVWI and RVWI, and myocardial apoptosis were reduced by treatment with HGF, which also increased the myocardial cell viability and the expression of HGF and c-Met. In summary, HGF significantly attenuates myocardial apoptosis and improves cardiac function after AMI in diabetic rats by further enhancing the activation of HGF/c-Met pathway.
Identifiants
pubmed: 32909423
doi: 10.4081/ejh.2020.3142
pmc: PMC7445436
doi:
Substances chimiques
Cardiotonic Agents
0
Hepatocyte Growth Factor
67256-21-7
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Res. 2015 Feb 1;75(3):605-14
pubmed: 25503558
Diabetes Res. 1985 Jul;2(4):191-3
pubmed: 3910327
Br J Pharmacol. 2007 Sep;152(2):175-88
pubmed: 17558439
Circulation. 1997 Jun 3;95(11):2552-8
pubmed: 9184586
Cardiovasc Res. 2001 Jul;51(1):41-50
pubmed: 11399246
Stem Cell Res Ther. 2017 Jun 15;8(1):146
pubmed: 28619106
Cancer Res. 1993 Nov 15;53(22):5355-60
pubmed: 7693339
Diabetes Metab Res Rev. 2015 Jan;31(1):85-92
pubmed: 24898423
Curr Cancer Drug Targets. 2017;17(3):297-302
pubmed: 28004613
J Thorac Oncol. 2010 May;5(5):591-6
pubmed: 20150826
Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(6):588-610
pubmed: 20551596
Biomed Res. 2015;36(1):11-9
pubmed: 25749147
Clin Gastroenterol Hepatol. 2018 Oct;16(10):1607-1615.e1
pubmed: 29702298
J Appl Bacteriol. 1979 Feb;46(1):57-63
pubmed: 438108
JAMA. 2002 May 15;287(19):2570-81
pubmed: 12020339
Hum Gene Ther. 2018 Apr;29(4):413-423
pubmed: 29409352
Hypertension. 2004 Sep;44(3):365-71
pubmed: 15289469
Br J Cancer. 2007 Aug 6;97(3):368-77
pubmed: 17667909
Gene. 2019 Jun 15;701:98-103
pubmed: 30905809
Mol Cells. 2010 Jan;29(1):9-19
pubmed: 20016947
Circulation. 2017 Aug 8;136(6):602-604
pubmed: 28784829
Biochimie. 2013 Jun;95(6):1177-84
pubmed: 23333744
Cell Mol Life Sci. 2011 May;68(10):1703-17
pubmed: 21327916
PLoS One. 2013 Nov 19;8(11):e81757
pubmed: 24260586
Artif Organs. 2012 Mar;36(3):238-46
pubmed: 21899570
Cancer Res. 2006 May 1;66(9):4742-9
pubmed: 16651427
Am J Med. 2018 Jul;131(7):778-786.e1
pubmed: 29596788
Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):95-101
pubmed: 24399329